ClinicalTrials.gg
TerminatedNCT01525225Updated Jun 22, 2015Results posted

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

A Phase 1 interventional study of Metformin immediate release (IR) and Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Terminated at 7 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by AstraZeneca · Phase 1 and Interventional

Why this study was terminated
Release of Post Marketing Requirement for this study. Terminated November 2013.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
274th of 287
4 · median 100
Started
2012
with 22 others
Phase 1
55 of 293
2 open now
Registered
145th of 293
by date
Lead sponsor
19 of 293
AstraZeneca

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 274th largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 55 in phase 1, and was the 145th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets

Read the detailed description

The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects aged 10 to 17 years with T2DM following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of T2DM
  • Male and female subjects ages 10-17
  • Body weight ≥50 kg
  • Glycosylated () 6.5 to 10%

Exclusion criteria

Exclusion Criteria:

  • Fasting plasma glucose (FPG) > 240 mg/dL at screening
  • Abnormal renal function
  • Active liver disease and/or significant abnormal liver function
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC

    Drug: Metformin immediate release (IR) · Drug: Saxagliptin · Drug: Metformin IR · Drug: Saxagliptin/Metformin XR FDC · Drug: Metformin XR

Interventions

  • Tablet, Oral, 1000 mg, twice daily, 1 day

    Also known as: Glucophage® IR

  • Tablet, Oral, 5 mg, single-dose, 1 day

  • Tablet, Oral, 1000 mg, twice daily, 5 days

    Also known as: Glucophage® IR

  • DrugSaxagliptin/Metformin XR FDC

    Drug pages: Saxagliptin · Metformin

    Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).

  • Tablet, Oral, 500 mg, Single-dose of 4 tablets

    Also known as: Glucophage® XR

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

    Time frame: Day 1 up to Day 8, plus 30 days

Secondary outcomes

  1. Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities

    Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-RX \>ULN or \>1.25\*ULN if Pre-RX \<=ULN; aspartate aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;alanine aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;blood urea nitrogen mmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.2\*Pre-RX if Pre-RX \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.25\*Pre-RX if Pre-RX \>ULN; creatine phosphokinase U/L: \>1.5\*Pre-RX if Pre-RX\>ULN or \>1.5\*ULN if Pre-RX \<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (%): \<0.85\*pre-RX;erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN.

    Time frame: Day 1 to Day 8

07

Results

Posted Aug 26, 2014
Limitations and caveats
Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated.

Participant flow

Upon approval of Kombiglyze™ XR, the Food and Drug Administration (FDA) required the conduct of this clinical pharmacology study in pediatric patients as a post-marketing requirement (PMR). Study was initiated February 2013. On 14-Nov-13, the FDA issued a letter stating release from this PMR, thus the study was terminated prior to completion.

Enrollment
Participant flow — Enrollment
MilestoneMetformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Started4
Completed2
Not completed2
Withdrew: No longer met study criteria1
Withdrew: Other1
Treated
Participant flow — Treated
MilestoneMetformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Started2
Completed2
Not completed0

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame:
Day 1 up to Day 8, plus 30 days
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death
participantsMetformin + Saxagliptin + Saxagliptin/Metformin XR FDC
AE2
Treatment-Related AE1
AE Leading to Discontinuation0
SAE0
Death0
SecondaryNumber of Participants With Marked Chemistry or Hematology Laboratory Abnormalities

Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-RX \>ULN or \>1.25\*ULN if Pre-RX \<=ULN; aspartate aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;alanine aminotransferase U/L: \>1.25\*Pre-RX if Pre-RX\>ULN or 1.25\*ULN if Pre-RX\<=ULN;blood urea nitrogen mmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.2\*Pre-RX if Pre-RX \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-RX \<=ULN or \>1.25\*Pre-RX if Pre-RX \>ULN; creatine phosphokinase U/L: \>1.5\*Pre-RX if Pre-RX\>ULN or \>1.5\*ULN if Pre-RX \<= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (%): \<0.85\*pre-RX;erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN.

Time frame:
Day 1 to Day 8
Reported as:
Number · participants
Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities
participantsMetformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities0

Adverse events

Collected over Day 1 up to Day 8, plus 30 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC—0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventMetformin + Saxagliptin + Saxagliptin/Metformin XR FDC
HeadacheNervous system disorders2/2

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Median13.0 (10.0 to 16.0)
Sex: Female, Male
Sex: Female, Male(Participants)Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Female2
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC
Black/African American1
White1
Region of Enrollment
Region of Enrollment(participants)Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC
United States2
08

Study locations

7 sites
  • Osborne Research Center
    Little Rock, Arkansas 72201, United States
  • Axis Clinical Trials
    Los Angeles, California 90036, United States
  • Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • The Children'S Mercy Hospital And Clinics
    Kansas City, Missouri 64108, United States
  • Promedica Toledo Children'S Hospital
    Toledo, Ohio 43606, United States
  • Promedica Toledo Childrens Hospital
    Toledo, Ohio 43606, United States
  • Childrens Hospital Of Pittsburgh Of Upmc
    Pittsburgh, Pennsylvania 15224, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2012
First posted
Feb 2, 2012
Start
Sep 2012
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 26, 2014
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01525225
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 2, 2012
Start date
Sep 2012
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 26, 2014
Last update
Jun 22, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Saxagliptin

Start the discussion